Curanex Pharmaceuticals (CURX) Common Equity (2024 - 2026)

Curanex Pharmaceuticals (CURX) has reported Common Equity for 3 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 1467.52% year-over-year to $4.8 million; the trailing twelve-month figure through Jun 2026 stood at $4.8 million (up 1467.52% YoY), and the FY2025 full-year result was $11.2 million, up 2128.84% from the prior year.
• Common Equity declined to $4.8 million in Q2 2026 per CURX's latest filing, from $11.2 million in the prior quarter.
• Across five years, Common Equity topped out at $14.3 million in Q3 2025 and bottomed at $305431.0 in Q2 2025.
• Historically, Common Equity has averaged $5.3 million across 3 years, with a median of $2.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity jumped 2189.81% in 2025, then jumped 1467.52% in 2026.
• Over 3 years, Common Equity stood at $503360.0 in 2024, then jumped by 2128.84% to $11.2 million in 2025, then tumbled by 57.33% to $4.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $4.8 million, $11.2 million, and $14.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.